- 121MarketSource · Medical Device Network
Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook
Dexcom reported 15% year-over-year revenue growth in Q1 but chose not to raise its full-year FY26 guidance, citing geopolitical uncertainties. The continuous glucose monitoring vendor maintained its prior outlook despite the stronger-than-expected quarterly performance.
- 122MarketSource · Medical Device Network
MintNeuro and Motif Neurotech collaborate for mental health therapies
MintNeuro and Motif Neurotech have entered a partnership to develop miniature brain-computer interface (BCI) therapy for mental health applications. The collaboration aims to advance BCI technology for therapeutic use, combining the companies' expertise in neural interfaces and neurotech innovation.
- 123MarketSource · Medical Device Network
GE HealthCare’s stock plunges 13% as supply chain costs bite
GE HealthCare lowered its 2026 growth forecast, citing rising freight costs and material expenses. The revision, a 3.3 percentage-point reduction at the top end of guidance, prompted a 13% stock decline. The move reflects broader supply chain pressures affecting the medical device manufacturer's outlook.
- 124MarketSource · Medical Device Network
Axoft raises $55m to advance BCI made of Fleuron
Axoft has raised $55 million in funding to advance clinical trials and US regulatory activities for its implantable brain-computer interface (BCI) device. The capital will support ongoing trial programmes and FDA pathway development for the technology.
- 125MarketSource · Mobi Health News
Nervonik raises $52.5M to enhance peripheral nerve stimulation system
Nervonik, a peripheral nerve stimulation device developer, closed a $52.5 million Series B funding round led by Amzak Health. The oversubscribed round included participation from Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital. The capital will support enhancement of the company's nerve stimulation platform.
- 126MarketSource · Mobi Health News
Aidoc secures $150M to scale AI imaging tools
Aidoc, an AI imaging software company, closed a $150 million Series E funding round led by Goldman Sachs Growth Equity, with participation from General Catalyst, SoftBank Investment Advisors, and NVIDIA Ventures. The round brings total capital raised to over $500 million. Aidoc develops AI-enabled tools for diagnostic imaging analysis.
- 127MarketSource · Medical Device Network
CareDx sharpens precision medicine focus with $260m Naveris acquisition
CareDx announced a $260 million acquisition of Naveris, a precision medicine company, as part of a strategic shift following the recent divestment of its lab products business. The move reflects CareDx's decision to refocus on precision medicine after its lab segment reported flat Q1 revenue.
- 128MarketSource · MedCity News
Beyond the Scale: How Imaging Can Help Determine GLP-1 Efficacy
Telehealth clinic Hone Health partnered with imaging vendor BodySpec to offer DEXA body composition scans to GLP-1 patients. The collaboration aims to help providers differentiate fat loss from muscle loss during treatment, enabling more detailed assessment of drug efficacy beyond weight metrics alone. The partnership represents a vendor strategy move to integrate diagnostic imaging into remote weight-management workflows.
- 129MarketSource · Mobi Health News
Courier Health scores $50M to scale CRM technology
Courier Health, a health tech platform serving life sciences manufacturers, closed a $50 million Series B funding round led by Oak HC/FT, with participation from Norwest and Work-Bench. The New York-based company provides CRM technology to help manufacturers manage customer relationships and sales operations.
- 130MarketSource · MedCity News
Top Silicon Valley VCs Are Backing a New Health Tech Residency Program
The AI Health Fund launched Treehub, a residency program for early-stage healthcare AI startups, backed by prominent venture investors including Tim Draper and Anne Wojcicki. The program targets companies at pre-formation stages, signaling continued capital flow into the health tech vendor ecosystem.
- 131MarketSource · Medical Device Network
Boston Scientific reports steady Q1 2026 performance yet tempers FY26 outlook
Boston Scientific reported 11.2% year-over-year growth in Q1 2026 but reduced its full-year 2026 revenue guidance, trimming the top-end growth outlook by 2 percentage points. The adjustment signals caution amid what the company characterized as steady near-term performance across its device portfolio.
- 132MarketSource · Medical Device Network
AcuityMD raises $80m for AI augmentation to medtech sales platform
AcuityMD secured $80 million in funding to expand its AI-powered sales platform serving medical device companies. The platform is designed to streamline commercial execution and sales operations for medtech vendors. The fresh capital will support integration of advanced AI capabilities into the existing system.
- 133MarketSource · Medical Design & Outsourcing
CPC Biotech debuts unified bioprocess fluid portfolio
CPC Biotech has launched as a unified brand combining CPC's biopharma connectors with PSG Biotech's pumps, flow meters, and sensors into an integrated bioprocess fluid management portfolio. The company will debut publicly at INTERPHEX 2026 in April at the Javits Center in New York City. The consolidation brings together critical fluid handling components and expertise for biopharmaceutical manufacturing.
- 134MarketSource · Medical Design & Outsourcing
Henry Schein discloses exec pay for longtime CEO Stan Bergman’s final year
Henry Schein disclosed executive compensation for 2025, reporting pay increases for three of five top executives in what marks longtime CEO Stan Bergman's final year leading the Melville, New York-based medical products distributor. The company also raised median employee compensation year-over-year. Bergman has led Henry Schein, ranked among the world's largest medical device suppliers, for an extended tenure.
- 135MarketSource · MedCity News
Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition
Eli Lilly acquired Kelonia Therapeutics for $3.2 billion to add an in vivo cell therapy program targeting multiple myeloma. The deal marks Lilly's third genetic medicines acquisition in as many years, following purchases of Verve and Orna Therapeutics, as the pharmaceutical giant diversifies its approach to in vivo genetic therapy across multiple platforms and disease targets.
- 136MarketSource · Medical Design & Outsourcing
Abbott’s device leader pay climbs again with double-digit sales growth
Abbott's EVP and Medical Devices Group President Lisa Earnhardt received a compensation package increase exceeding 20% in 2025, reflecting double-digit sales growth in the division. Abbott ranked eighth globally among medical device companies by revenue in the latest Medtech Big 100 rankings. The pay rise underscores strong financial performance in the device segment amid broader market momentum.
- 137MarketSource · Medical Design & Outsourcing
Switchback Medical is expanding into Costa Rica
Switchback Medical, a medical device contract development and manufacturing organization, has signed a lease for an 18,000-square-foot facility in Costa Rica's Coyol Free Trade Zone. The expansion marks the company's first international manufacturing footprint outside its Brooklyn Park, Minnesota headquarters, signaling a strategic shift in production capacity and supply-chain positioning for the CDMO sector.
- 138MarketSource · Medical Design & Outsourcing
CDMO Arterex upgrades manufacturing facility near Boston
Arterex, a contract device manufacturer, is expanding its Mansfield, Massachusetts facility by 15,000 square feet and installing a new steam sterilizer to boost operational capacity by nearly 50%. The upgrade aims to improve inventory control and logistics efficiency for its contract manufacturing customers.
- 139MarketSource · Medical Design & Outsourcing
Medtech CDMO Integer discloses executive pay after new CEO steps in
Integer Holdings Corp., a contract manufacturer and CDMO for medical devices, disclosed executive compensation packages following a new CEO appointment in an SEC filing. The company also reported a significant increase in median employee pay. Integer ranks among the top 60 medical device companies globally.
- 140MarketSource · Fierce Healthcare
Whoop raises $575M series G, Abbott comes on board amid hiring spree
Whoop, a fitness wearable maker, raised $575 million in Series G funding with Abbott as a new investor. The round comes as Whoop expands hiring and positions itself for growth in the consumer health monitoring space. Abbott's participation signals potential distribution or integration opportunities between the companies.
- 141MarketSource · Fierce Healthcare
Medline makes Nasdaq debut, raising $6.26B in year's largest IPO
Medline Industries completed its Nasdaq initial public offering, raising $6.26 billion in the largest IPO of 2024. The medical device and supply distributor, previously held by private equity, transitions to public ownership. The offering marks a significant milestone for one of the U.S.'s largest medical equipment and consumables vendors and signals investor appetite for established medical-supply businesses.
- 142MarketSource · Fierce Healthcare
GE HealthCare to acquire imaging software provider Intelerad for $2.3B
GE HealthCare announced a $2.3 billion acquisition of Intelerad, a cloud-based imaging software provider serving radiology, cardiology, and clinical trial workflows. The deal expands GE HealthCare's outpatient imaging portfolio and complements its existing in-hospital imaging infrastructure. Intelerad's platform serves independent practices and healthcare networks with DICOM viewing, management, and AI-enabled analysis tools.
- 143MarketSource · Fierce Healthcare
Abbott dives into cancer diagnostics with $23B buyout of Exact Sciences
Abbott announced a $23 billion acquisition of Exact Sciences, the developer of Cologuard and blood-based cancer screening tests. The deal marks the largest diagnostics acquisition to date and significantly expands Abbott's oncology diagnostic portfolio, combining Exact Sciences' colorectal and multi-cancer detection platforms with Abbott's existing diagnostic infrastructure and distribution capabilities.
- 144MarketSource · Fierce Healthcare
Tempus claims AI pathology developer Paige in $81M deal
Tempus acquired AI pathology developer Paige for $81 million, gaining access to a dataset of nearly 7 million digitized pathology slides and associated clinical data from Memorial Sloan Kettering Cancer Center. The acquisition adds Paige's machine-learning capabilities in digital pathology to Tempus's oncology-focused platform.
- 145MarketSource · Fierce Healthcare
Philips to invest $150M in US manufacturing base, including ultrasound site expansion
Philips announced a $150 million investment in its U.S. manufacturing footprint, including expansion of a Pennsylvania facility dedicated to hospital ultrasound equipment production. The move reflects the company's strategy to strengthen domestic manufacturing capacity for imaging hardware.
- 146MarketSource · Fierce Healthcare
Ultromics nets $55M to boost its AI ultrasound software for detecting hidden heart failure
Ultromics secured $55 million in venture funding to scale its AI-driven ultrasound software platform for detecting occult heart failure. The funding will support commercial expansion of the company's diagnostic tools, which use machine learning to identify cardiac abnormalities from echocardiography images that may be missed by conventional analysis.